by According to Precedence Research’s new research study on “Systemic Inflammatory Response Syndrome Treatment Market Size 2021 to 2030 – Global Industry Analysis and Forecast (By Product Type: Meningitis, Urinary Tract Infection (UTI), Pneumonia, Autoimmune Diseases, and Others; By Application: Hospital & Ambulatory Surgical Centers, Specialty Clinics, and Others)” the global systemic inflammatory response syndrome treatment market size is forecasted to reach around US$ 21.36 billion and is anticipated to grow with a healthy CAGR of 7.37% from 2021 to 2030.
The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.
Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1245
SIRS (systemic inflammatory response syndrome) can be described as an extreme defensive retort by the human body to a lethal source of strain to trace and later eliminate the endogenic or exogenic source of the offense such as trauma, infection, acute inflammation, surgery, reperfusion, ischemia, or malignancy. It comprises the advent of short-duration reactants that are straight mediators of the issue’s extensive immunological, endocrine, hematological, and autonomic alteration.
The deregulated cytokine storm has the potential to trigger a major inflammatory cascade contributing to reversible or irreversible end-organ dysfunction and even death, even though the aim is protective. Sepsis is one type of systemic inflammatory response syndrome with a suspected cause of infection. Sepsis is considered extreme sepsis with one or more end-organ failures and septic shock with hemodynamic dysfunction despite intravascular volume repletion. Together, they represent a physiological pathway that eventually further deteriorates the equilibrium between pro and anti-inflammatory responses.
Scope of the Report
| Report Highlights | Details |
| Market Size | US$ 21.36 billion by 2030 |
| Growth Rate | CAGR of 7.37% from 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Application |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Growth Factors:
Increase in frequency of Systemic Inflammatory Response Syndrome, prominence of Systemic Inflammatory Response Syndrome Treatment to remain strong for urinary tract infection treatment are among major factors boosting growth of the global industry. Additionally, technological advancements and integration of latest technologies is fueling growth of the systemic inflammatory response syndrome treatment market worldwide. Moreover, high investment by major players in research and development is having positive impact on the growth of global industry. Further, increased focus on the improvement of healthcare infrastructure in developing regions and growing awareness regarding early diagnosis are other factors to boost growth of the global market during the forecast time frame.
One of the key factors for assessing post-surgical complications and end-organ dysfunction is systemic inflammatory response syndrome. Syndrome progression is linked to lengthy hospital stays, high incidence of multiple organ dysfunction, and elevated morbidity.
In cardiac surgery, Systemic Inflammatory Response Syndrome is among the popular post-operative complications, leading to organ failure or even death. It is expected that the prevalence of Systemic Inflammatory Response Syndrome among pediatric patients will increase in the near future.
The University Of Colorado School Of Medicine released an article claiming that 40,356 pediatric patients met inclusion requirements out of 56,210 visits to emergency departments over a 1-year study period. Patients with Systemic Inflammatory Response Syndrome vital signs accounted for 92.8 per cent of all visits with fever > 38.5 ° C among the sample population included.
Apart from therapies, the development of numerous pipeline drugs is also led by extensive efforts supported by central and private funding. For example, Adrecizmab, which is considered efficient for the treatment of septic shock, was introduced by Adrenomed AG. The medication is also effective in preventing vascular damage and keeping ideal vascular functions intact. Thus, Therapeutics and pipeline drugs, driven by efficiency, are projected to maintain demand in the treatment market for systemic inflammatory response syndrome in the future.
Report Highlights:
- Based on product type, autoimmune diseases reported largest revenue in 2020. This is accredited to high incidence of autoimmune disorders.
- On the basis of application, hospital & ambulatory surgical centers accounted for the weighty share in the target industry. This is due to availability of latest infrastructure.
- GlaxoSmithKline and AstraZeneca are major companies operating in the global systemic inflammatory response syndrome treatment market.
Regional Analysis:
The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 39%. U.S. represented the highest share in the North American region primarily due to presence of modern healthcare infrastructure, and availability of latest products. Moreover, growing prevalence of SIRS (systemic inflammatory response syndrome) is expected to have positive impact on the industry growth. Europe is expected to account for the second largest share in the systemic inflammatory response syndrome treatment industry in terms of revenue in 2020. The growth in the European region is attributed to encouraging reimbursement scenario, presence of skilled researchers, and technological innovations. Asia Pacific is anticipated to grow at the highest CAGR during the projected time-duration majorly due to high investment by major market players and increasing expenditure on healthcare services. Growth in the research and development activities is a major factor that is projected to have optimistic impact on the growth of the target industry in the Asian countries.
Some of the prominent players in the global systemic inflammatory response syndrome treatment market are listed as below:
- GlaxoSmithKline
- AstraZeneca
- CytoSorbents Corporation
- Cardinal Health
- Asahi Kasei
- ConvaTec
- CHIESI Farmaceutici
- Smith & Nephew
For improved status of systemic inflammatory response syndrome treatment, and strategies accepted by Precedence Research projected the upcoming growth of the systemic inflammatory response syndrome treatment market.
Key Market Developments:
- In year 2020, Aferetica SRL and the Cyto Sorbents Corporation announced the approval of CytoSorbents’ ECOS-300CY sorbent cartridge and Aferetica’s PerLife ex vivo organ perfusion system by the European Union.
Major Market Segments Covered:
By Product Type
- Urinary Tract Infection (UTI)
- Autoimmune Diseases
- Meningitis
- Pneumonia
- Others
By Application
- Specialty Clinics
- Hospital & Ambulatory Surgical Centers
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- United Kingdom
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Systemic Inflammatory Response Syndrome Treatment Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Systemic Inflammatory Response Syndrome Treatment Market
5.1. Covid-19: Systemic Inflammatory Response Syndrome Treatment Industry Impact
5.2. Systemic Inflammatory Response Syndrome Treatment Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Systemic Inflammatory Response Syndrome Treatment Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Systemic Inflammatory Response Syndrome Treatment Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Systemic Inflammatory Response Syndrome Treatment Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increase in frequency of Systemic Inflammatory Response Syndrome
6.1.1.2. Prominence of Systemic Inflammatory Response Syndrome Treatment to remain strong for urinary tract infection treatment
6.1.2. Market Restraints
6.1.2.1. Low Awareness
6.1.3. Market Opportunities
6.1.3.1. Technological advancements and integration of latest technologies
Chapter 7. Global Systemic Inflammatory Response Syndrome Treatment Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Systemic Inflammatory Response Syndrome Treatment Market Revenue by Market Players (2017 – 2020)
7.1.1.2. Systemic Inflammatory Response Syndrome Treatment Market Revenue Market Share by Market Players (2017 – 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Systemic Inflammatory Response Syndrome Treatment Market, By Product Type
8.1. Systemic Inflammatory Response Syndrome Treatment Market, by Product Type, 2017-2030
8.1.1. Urinary Tract Infection (UTI)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Autoimmune Diseases
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Meningitis
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Pneumonia
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Systemic Inflammatory Response Syndrome Treatment Market, By Application
9.1. Systemic Inflammatory Response Syndrome Treatment Market, by Application, 2017-2030
9.1.1. Specialty Clinics
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hospital & Ambulatory Surgical Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Systemic Inflammatory Response Syndrome Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue Forecast by Product Type(2017-2030)
10.1.2. Market Revenue Forecast by Application (2017-2030)
10.1.3. U.S
10.1.3.1. Market Revenue Forecast (2017-2030)
10.1.4. Canada
10.1.4.1. Market Revenue Forecast (2017-2030)
10.2. Europe
10.2.1. Market Revenue Forecast by Product Type (2017-2030)
10.2.2. Market Revenue Forecast by Application (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue Forecast (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue Forecast (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue Forecast (2017-2030)
10.2.6. Rest of EU
10.2.6.1. Market Revenue Forecast (2017-2030)
10.3. Asia Pacific (APAC)
10.3.1. Market Revenue Forecast by Product Type (2017-2030)
10.3.2. Market Revenue Forecast by Application (2017-2030)
10.3.3. China
10.3.3.1. Market Revenue Forecast (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue Forecast (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue Forecast (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue Forecast (2017-2030)
10.4. LATAM
10.4.1. Market Revenue Forecast by Product Type (2017-2030)
10.4.2. Market Revenue Forecast by Application (2017-2030)
10.4.3. Brazil
10.4.3.1. Market Revenue Forecast (2017-2030)
10.4.4. Rest of LATAM
10.4.4.1. Market Revenue Forecast (2017-2030)
10.5. Middle East and Africa (MEA)
10.5.1. Market Revenue Forecast by Product Type (2017-2030)
10.5.2. Market Revenue Forecast by Application (2017-2030)
10.5.3. GCC
10.5.3.1. Market Revenue Forecast (2017-2030)
10.5.4. North Africa
10.5.4.1. Market Revenue Forecast (2017-2030)
10.5.5. South Africa
10.5.5.1. Market Revenue Forecast (2017-2030)
10.5.6. Rest of MEA
10.5.6.1. Market Revenue Forecast (2017-2030)
Chapter 11. Company Profiles
11.1. GlaxoSmithKline
11.1.1. Company Overview, Business Information, Regional Presence
11.1.2. Product Portfolio Analysis
11.1.2.1. Product Details, Specification, Application
11.1.3. Revenue, Price, and Gross Margin (2017-2020)
11.1.4. Recent Developments and Strategies
11.2. AstraZeneca
11.2.1. Company Overview, Business Information, Regional Presence
11.2.2. Product Portfolio Analysis
11.2.2.1. Product Details, Specification, Application
11.2.3. Revenue, Price, and Gross Margin (2017-2020)
11.2.4. Recent Developments and Strategies
11.3. CytoSorbents Corporation
11.3.1. Company Overview, Business Information, Regional Presence
11.3.2. Product Portfolio Analysis
11.3.2.1. Product Details, Specification, Application
11.3.3. Revenue, Price, and Gross Margin (2017-2020)
11.3.4. Recent Developments and Strategies
11.4. Cardinal Health
11.4.1. Company Overview, Business Information, Regional Presence
11.4.2. Product Portfolio Analysis
11.4.2.1. Product Details, Specification, Application
11.4.3. Revenue, Price, and Gross Margin (2017-2020)
11.4.4. Recent Developments and Strategies
11.5. Asahi Kasei
11.5.1. Company Overview, Business Information, Regional Presence
11.5.2. Product Portfolio Analysis
11.5.2.1. Product Details, Specification, Application
11.5.3. Revenue, Price, and Gross Margin (2017-2020)
11.5.4. Recent Developments and Strategies
11.6. ConvaTec
11.6.1. Company Overview, Business Information, Regional Presence
11.6.2. Product Portfolio Analysis
11.6.2.1. Product Details, Specification, Application
11.6.3. Revenue, Price, and Gross Margin (2017-2020)
11.6.4. Recent Developments and Strategies
11.7. CHIESI Farmaceutici
11.7.1. Company Overview, Business Information, Regional Presence
11.7.2. Product Portfolio Analysis
11.7.2.1. Product Details, Specification, Application
11.7.3. Revenue, Price, and Gross Margin (2017-2020)
11.7.4. Recent Developments and Strategies
11.8. CHIESI Farmaceutici
11.8.1. Company Overview, Business Information, Regional Presence
11.8.2. Product Portfolio Analysis
11.8.2.1. Product Details, Specification, Application
11.8.3. Revenue, Price, and Gross Margin (2017-2020)
11.8.4. Recent Developments and Strategies
11.9. Orion Corporation
11.9.1. Company Overview, Business Information, Regional Presence
11.9.2. Product Portfolio Analysis
11.9.2.1. Product Details, Specification, Application
11.9.3. Revenue, Price, and Gross Margin (2017-2020)
11.9.4. Recent Developments and Strategies
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1245
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
